Header

UZH-Logo

Maintenance Infos

Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer


Wujanto, Caryn; Vellayappan, Balamurugan; Siva, Shankar; Louie, Alexander V; Guckenberger, Matthias; Slotman, Ben J; Onishi, Hiroshi; Nagata, Yasushi; Liu, Mitchell; Lo, Simon S (2019). Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer. Frontiers in Oncology, 9:01219.

Abstract

Metastatic non-small cell lung cancer (NSCLC) is associated with a limited survival when treated with palliative intent platinum-based chemotherapy alone. Recent advances in imaging and therapeutic strategy have identified a subset of patients with limited metastases who may benefit from early local ablative therapy with either surgery or radiotherapy, in addition to standard treatment. Stereotactic body radiotherapy (SBRT) is increasingly used in the treatment of extra-cranial oligometastatic NSCLC (OM-NSCLC) due its non-invasive conduct and ability to deliver high doses. Clinical evidence supporting the use of SBRT in OM-NSCLC is emerging and consistently demonstrates significant benefit in local control and progression-free survival. Here, we discuss the definition of oligometastases (OM), review current available data on SBRT treatment in extra-cranial OM-NSCLC including evidence for site-specific SBRT in lung, liver, and adrenal metastases.

Abstract

Metastatic non-small cell lung cancer (NSCLC) is associated with a limited survival when treated with palliative intent platinum-based chemotherapy alone. Recent advances in imaging and therapeutic strategy have identified a subset of patients with limited metastases who may benefit from early local ablative therapy with either surgery or radiotherapy, in addition to standard treatment. Stereotactic body radiotherapy (SBRT) is increasingly used in the treatment of extra-cranial oligometastatic NSCLC (OM-NSCLC) due its non-invasive conduct and ability to deliver high doses. Clinical evidence supporting the use of SBRT in OM-NSCLC is emerging and consistently demonstrates significant benefit in local control and progression-free survival. Here, we discuss the definition of oligometastases (OM), review current available data on SBRT treatment in extra-cranial OM-NSCLC including evidence for site-specific SBRT in lung, liver, and adrenal metastases.

Statistics

Citations

Altmetrics

Downloads

8 downloads since deposited on 04 Feb 2020
8 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Radiation Oncology
Dewey Decimal Classification:610 Medicine & health
Uncontrolled Keywords:Cancer Research, Oncology
Language:English
Date:12 November 2019
Deposited On:04 Feb 2020 13:25
Last Modified:01 Mar 2020 14:39
Publisher:Frontiers Research Foundation
ISSN:2234-943X
OA Status:Gold
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.3389/fonc.2019.01219
PubMed ID:31799188

Download

Gold Open Access

Download PDF  'Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer'.
Preview
Content: Published Version
Filetype: PDF
Size: 357kB
View at publisher
Licence: Creative Commons: Attribution 4.0 International (CC BY 4.0)